Key Takeaways
- The UHMS maintains 14 approved HBOT indications spanning emergency care, wound care, and specific sensorineural conditions.
- US Medicare (CMS) reimbursement generally follows the UHMS list; FDA chamber clearances are tied to it.
- Most UHMS indications are treated at 2.4 ATA; emergency indications (CO, DCS, gas gangrene) use 2.8–3.0 ATA.
- Course lengths range from 1–5 sessions (emergency) to 20–40 sessions (wound care).
- Off-label indications (TBI, stroke, long COVID, fibromyalgia, autism, PTSD, anti-aging) are generally not covered by insurance.
- Sudden sensorineural hearing loss was added to CMS coverage in 2021 — the most recent major expansion.
Why the UHMS List Matters
The Undersea and Hyperbaric Medical Society (UHMS) is the international clinical authority for hyperbaric medicine. The UHMS-approved indications list defines where the evidence base is considered sufficient to recommend HBOT. In the US, CMS reimbursement follows this list, and FDA chamber clearances are predicated on it.
The 14 Indications
- Air or gas embolism — iatrogenic or diving-related. Immediate recompression is life-saving.
- Carbon monoxide poisoning (including smoke inhalation) — the Weaver 2002 protocol reduces delayed neurocognitive sequelae.
- Clostridial myositis and myonecrosis (gas gangrene) — HBOT suppresses alpha-toxin production and supports surgical/antibiotic management.
- Crush injury, compartment syndrome, and acute traumatic ischaemia — reduces reperfusion injury and oedema.
- Decompression sickness — US Navy Treatment Table 6 (2.8 ATA) is the standard of care.
- Enhancement of healing in selected problem wounds — primarily diabetic foot ulcers Wagner Grade 3+.
- Severe anaemia (exceptional blood loss anaemia) — temporary tissue oxygenation when blood transfusion is unavailable or inadequate.
- Intracranial abscess — adjunct to surgical drainage and antibiotics.
- Necrotising soft-tissue infection — adjunct to surgical debridement.
- Chronic refractory osteomyelitis — selected cases unresponsive to standard care.
- Delayed radiation injury (soft tissue and bony) — well-established for osteoradionecrosis and radiation cystitis/proctitis.
- Compromised skin grafts and flaps — enhances survival of threatened grafts.
- Thermal burns — adjunct for selected cases of significant burn injury.
- Sudden sensorineural hearing loss — adjunct to steroid therapy, time-sensitive within the first 2–4 weeks.
What's NOT on the List
Several widely marketed off-label HBOT indications are not UHMS-approved and generally not covered by insurance:
- Traumatic brain injury (TBI)
- Stroke recovery (chronic phase)
- Long COVID
- Fibromyalgia
- Autism spectrum disorder
- PTSD
- Age-related cognitive decline / "anti-aging"
- Sports recovery
These may have genuine clinical evidence (TBI, stroke, long COVID in particular have RCT-level data), but they are considered research-stage by UHMS. Patients pursuing HBOT for these indications almost always pay out of pocket.
Protocol Pressures
Most UHMS-approved indications are treated at 2.4 ATA, which is the pressure CMS reimbursement is pegged to. Carbon monoxide, decompression sickness, and gas gangrene use higher pressures (2.8–3.0 ATA). The duration of a course varies dramatically: 1–5 sessions for emergency indications, 20–40 for most wound care, 30–40 for radiation injury.
Finding an Accredited Facility
UHMS maintains a facility accreditation programme in the US. Choosing an accredited facility is strongly recommended for any medical HBOT. Accreditation covers staff training, chamber maintenance, emergency protocols, and quality assurance.
Frequently Asked Questions
Why is TBI not UHMS-approved despite the Efrati trials?
UHMS requires a specific threshold of RCT evidence plus clinical consensus. The Efrati Lab evidence for TBI is growing but has not yet triggered formal UHMS review. Pressure is building for revised consideration.
Can I pursue off-label HBOT at a UHMS facility?
Some UHMS-accredited facilities also offer off-label HBOT on a cash-pay basis; policies vary by facility. Private hyperbaric clinics are more common for off-label protocols.
How is UHMS different from the FDA?
UHMS is a professional clinical society; FDA is a regulatory agency. UHMS maintains the clinical indications list. FDA clears the chamber devices themselves. CMS/Medicare coverage links the two through the UHMS indications list.
How often is the UHMS list updated?
The UHMS Indications Manual is revised periodically — the 14th edition was published in 2019. Individual indications can be added or modified between full-manual revisions following formal UHMS review processes.
